Alvotech (ALVO)

Market Cap	1.45B
Revenue (ttm)	573.35M
Net Income (ttm)	69.50M
Shares Out	313.02M
EPS (ttm)	0.24
PE Ratio	19.32
Forward PE	33.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	327,697
Open	4.790
Previous Close	4.730
Day's Range	4.610 - 4.860
52-Week Range	4.320 - 13.700
Beta	0.11
Analysts	Buy
Price Target	9.25 (+99.35%)
Earnings Date	Nov 12, 2025

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO
• Website: https://www.alvotech.com

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price target is $9.25, which is an increase of 99.35% from the latest price.

Price Target

$9.25

(99.35% upside)

Analyst Consensus: Buy